ClinicalTrials.gg
RecruitingNCT07463495TRIMETUpdated Mar 16, 2026

The Metabolic Effects of Oral Tributyrin Administration

An interventional study of tributyrin and Control in Healthy Overweight/Obese, sponsored by University of Aarhus. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by University of Aarhus · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Obesity by University of Aarhus — 5 open to participants now, 7 under way, none of them phase 3. Obesity · University of Aarhus.

Planned enrollment
22nd of 26
12 · median 30
Started
2026
the only one that year
No phase
24 of 40
3 open now
Registered
40th of 40
by date

Among the 40 studies in Obesity by University of Aarhus, this one is the 22nd largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2026, is one of 24 with no phase, and was the 40th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 40 studies in Obesity by University of Aarhus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Obesity by University of Aarhus, or all of them as a file.
02

Study summary

The goal of this double-blinded randomized clinical cross-over trial is to investigate the metabolic and appetite regulating effects of oral tributyrin (a butyrate pro-drug) administration vs placebo.

The main questions it aims to answer are:

  • Does tributyrin have glucose lowering properties in humans?
  • Does tributyrin reduce appetite in humans?

A sample size calculation estimated a minimum of 10 participants. We expect to include 12 participants in this study. Tributyrin or placebo is ingested once or twice daily for 2x2 weeks, separated by a washout period of minimum 2 weeks. On trial day following each 2-week period we assess:

  • Postprandial blood sugar levels
  • Hunger sensations (questionnaire)
  • Enteroendocrine hormone secretion (GLP-1, GIP, PYY, LEAP2, ghrelin)
  • Cardiac function (echocardiography) - An exploratory study evaluating the hemodynamic effects assessed by echocardiography is anticipated to be published separately.
  • Caloric intake (ad libitum meal test)
  • Gastric emptying rate (acetaminophen test)
  • Resting metabolic rate (indirect calorimetry).

While at home, subjects will wear a sleep monitoring device for three consecutive nights and deliver fecal samples for analysis of short-chain fatty acid content and microbiota composition.

03

Conditions studied

  • Healthy Overweight/Obese

Browse trials for

Keywords

  • Appetite
  • Glucose metabolism
  • Butyrate
  • Tributyrin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A (BMI) between 30-45 kg/m2
  • Older than 18 years of age
  • \< 48 mmol/mol
  • within normal range (females: 7.3-9.5 mmol/L, males: 8.3-10.5 mmol/L)
  • Written and oral consent to participate

Exclusion criteria

Exclusion Criteria:

  • Medications affecting glucose metabolism and/or appetite (e.g. insulin, metformin, GLP-1 analogues)
  • Special diet (HCLF, ketogenic diets, vegan/vegetarian)
  • Ongoing cancer or other acute/chronic serious diseases (determined by PI)
  • Inability to understand Danish or English
  • Abnormal blood samples at screening visit (determined by PI and co-investigators)
  • Deemed unsuitable to participate by the PI and co-investigators
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Oral tributyrin

    Oral ingestion of tributyrin

    Dietary Supplement: tributyrin

  • Placebo comparator
    Control

    Oral ingestion of placebo

    Dietary Supplement: Control

Interventions

  • Dietary supplementtributyrin

    Oral ingestion of tributyrin (liquid) once daily (20 g x 1) for 7 days, then twice daily (20 g x 2) for 7 days.

  • Dietary supplementControl

    Oral ingestion of water (liquid) with added bitter substance once daily (20 ml x 1) for 7 days, then twice daily (20 ml x 2) for 7 days

06

What researchers measure

Primary outcomes

  1. Postprandial glucose

    iAUC of plasma glucose after ingestion of mixed meal

    Time frame: During trial day, time 120-300 minutes

Secondary outcomes

  1. Butyrate

    Plasma concentrations of butyrate

    Time frame: During trial day, time 0-300 minutes

  2. Subjective appetite - appetite questionaire

    We will assess subjective appetite sensations with a recommended primary scale for self-reported appetite in healthy adults. The scale includes five questions addressing hunger, fullness, satiety, desire to eat and prospective consumption. The participants answer on a computer or tablet by sliding a button on a horizontal line (Visual Analog Scale) with left being eg. "Not hungry at all" to right "As hungry as I have ever felt".

    Time frame: 0, 60, 120, 180, 240, 300 minutes

  3. Caloric intake

    Caloric intake (kcal) during ad libitum meal test

    Time frame: Time 300 minutes

  4. Gastric emptying assessed by acetaminophen

    Plasma concentration of acetaminophen following oral acetaminophen intake

    Time frame: From ingestion of mixed meal test with acetaminophen, time 120-240 minutes

  5. GLP-1

    Plasma concentrations of GLP-1

    Time frame: During trial day, time 0-300 minutes

  6. GIP

    Plasma concentrations of GIP

    Time frame: During trial day, time 0-300 minutes

  7. LEAP2

    Plasma concentrations of LEAP2

    Time frame: During trial day, time 0-300 minutes

  8. PYY

    Plasma concentrations of PYY

    Time frame: During trial day, time 0-300 minutes

  9. Ghrelin

    Plasma concentrations of ghrelin

    Time frame: During trial day, time 0-300 minutes

  10. Insulin

    Plasma concentrations of insulin

    Time frame: During trial day, time 0-300 minutes

  11. C-peptide

    Plasma concentrations of c-peptide

    Time frame: During trial day, time 0-300 minutes

  12. Glucagon

    Plasma concentrations of glucagon

    Time frame: During trial day, time 0-300 minutes

  13. Cardiac function

    Echocardiographic assessment of cardiac output, left ventricular ejection fraction, global longitudinal strain, tricuspid annular plane systolic excursion (TAPSE), systemic vascular resistance

    Time frame: Time 0 and 90 minutes

  14. β-hydroxybutyrate

    Plasma concentrations of β-hydroxybutyrate

    Time frame: During trial day, time 0-300 minutes

  15. Lactate

    Plasma concentrations of lactate

    Time frame: During trial day, time 0-300 minutes

  16. C-reactive protein (CRP)

    Plasma concentrations of CRP

    Time frame: On trial day, time 0 minutes

  17. Tumor Necrosis Factor ⍺ (TNF-⍺)

    Plasma concentrations of TNF-⍺

    Time frame: On trial day, time 0 minutes

  18. Interleukin 6 (IL-6)

    Plasma concentrations of IL-6

    Time frame: On trial day, time 0 minutes

  19. Interleukin 10 (IL-10)

    Plasma concentrations of IL-10

    Time frame: On trial day, time 0 minutes

  20. Lipopolysaccharide Binding Protein (LPB)

    Plasma concentrations of LPB

    Time frame: On trial day, time 0 minutes

  21. Cortisol

    Plasma concentration of cortisol

    Time frame: On trial day, time 0 minutes

  22. Triglyceride

    Plasma concentrations of triglyceride

    Time frame: During trial day, time 0-300 minutes

  23. FFA

    Plasma concentrations of free fatty acids

    Time frame: During trial day, time 0-300 minutes

  24. Energy expenditure

    Indirect calorimetry

    Time frame: After 60 and 150 minutes approximately

  25. Sleep

    Assessment of sleep duration and stages

    Time frame: Three nights at the end of the 2 week period at home

  26. Fecal butyrate

    Fecal concentrations of butyrate

    Time frame: Day 0, 7, 14 during the 2 week period

  27. Microbiome composition

    Analysis of microbiome composition and metagenomics performed on fecal samples

    Time frame: Day 0, 7, 14 during the 2 week period

07

Study locations

1 of 1 sites recruiting
  • SDCA / Medical Research Laboratory
    Aarhus N, 8200, Denmark
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — The corresponding author will make data available on reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 10 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 11, 2026
StartActual
Feb 20, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07463495
Responsible party
Sponsor
First posted
Mar 11, 2026
Start date
Feb 20, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 16, 2026

Study contacts

Simon M Denning, MD
Contact
simon.denning@clin.au.dk
0045 78450000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tributyrin

Start the discussion